Published in Indian J Dermatol on January 01, 2009
A pilot study of the association of tumor necrosis factor alpha polymorphisms with psoriatic arthritis in the Romanian population. Int J Mol Sci (2011) 0.79
Belimumab in Systemic Lupus Erythematosus. Indian J Dermatol (2016) 0.75
Anti-TNFα Therapy in Inflammatory Lung Diseases bn. Pharmacol Ther (2017) 0.75
Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature (2003) 22.89
Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med (2003) 14.60
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med (2004) 14.53
The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell (2001) 12.59
Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol (2003) 10.21
The biology of cachectin/TNF--a primary mediator of the host response. Annu Rev Immunol (1989) 9.63
Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med (1991) 8.78
Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med (2006) 7.76
Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol (1989) 7.69
Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science (1992) 5.36
Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med (2003) 4.67
Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet (2001) 4.66
Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum (2004) 4.58
Etanercept as monotherapy in patients with psoriasis. N Engl J Med (2003) 4.57
Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med (2007) 4.12
Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum (2004) 3.92
A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med (2003) 3.67
IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol (2001) 3.32
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet (2001) 3.19
Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med (2003) 3.17
Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum (1996) 2.96
Interleukin 6 and its receptor: ten years later. Int Rev Immunol (1998) 2.96
The role of B cells in lpr/lpr-induced autoimmunity. J Exp Med (1994) 2.61
CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest (1999) 2.58
The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum (2006) 2.54
Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost (2003) 2.49
Design of effective immunotherapy for human autoimmunity. Nature (2005) 2.48
Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med (2006) 2.45
Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum (2004) 2.35
Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production. Am J Physiol Regul Integr Comp Physiol (2001) 2.16
Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum (2008) 2.02
Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol (2004) 1.66
Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol (2006) 1.58
How TNF was recognized as a key mechanism of disease. Cytokine Growth Factor Rev (2007) 1.55
The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum (2005) 1.51
Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. Lab Invest (2000) 1.50
Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis. J Invest Dermatol (2007) 1.41
Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Curr Opin Pharmacol (2004) 1.41
Revisiting the Koebner phenomenon: role of NGF and its receptor system in the pathogenesis of psoriasis. Am J Pathol (2008) 1.34
Adverse reactions to TNF-alpha inhibitors in rheumatoid arthritis. Lancet (2002) 1.30
The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: a population-based study. Arthritis Rheum (2006) 1.23
Nerve growth factor mediates hyperalgesia and cachexia in auto-immune arthritis. Pain (2005) 1.20
Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) abrogates disease activity in murine collagen-induced arthritis. Gene Ther (2003) 1.18
Placenta growth factor (PlGF) induces vascular endothelial growth factor (VEGF) secretion from mononuclear cells and is co-expressed with VEGF in synovial fluid. Clin Exp Immunol (2000) 1.16
Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis (2007) 1.16
VEGF and PlGF: two pleiotropic growth factors with distinct roles in development and homeostasis. Cell Tissue Res (2003) 1.11
Cytokines in autoimmune disorders. Int Rev Immunol (1998) 1.08
Tumor necrosis factor family ligand-receptor binding. Curr Opin Struct Biol (2004) 1.07
Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis. Arthritis Rheum (2006) 0.99
Immunomodulatory properties of FK734, a humanized anti-CD28 monoclonal antibody with agonistic and antagonistic activities. Transplantation (2007) 0.92
K252a, a high-affinity nerve growth factor receptor blocker, improves psoriasis: an in vivo study using the severe combined immunodeficient mouse-human skin model. J Invest Dermatol (2004) 0.91
Alefacept therapy produces remission for patients with chronic plaque psoriasis. Br J Dermatol (2003) 0.89
FR255734, a humanized, Fc-Silent, Anti-CD28 antibody, improves psoriasis in the SCID mouse-psoriasis xenograft model. J Invest Dermatol (2008) 0.88
The treatment of psoriasis with IL-10: rationale and review of the first clinical trials. Expert Opin Investig Drugs (2000) 0.76
Treatment of inflammatory dermatoses by tumour necrosis factor antagonists. J Eur Acad Dermatol Venereol (2006) 0.76
Characterization of the in vitro and in vivo activity of monoclonal antibodies to human IL-18. Hybridoma (2000) 0.76
Nerve growth factor: A key local regulator in the pathogenesis of inflammatory arthritis. Arthritis Rheum (2011) 1.57
Revisiting the Koebner phenomenon: role of NGF and its receptor system in the pathogenesis of psoriasis. Am J Pathol (2008) 1.34
IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem (2011) 1.17
Inflammation, atherosclerosis, and psoriasis. Clin Rev Allergy Immunol (2013) 1.10
Incidence and nature of infectious disease in patients treated with anti-TNF agents. Autoimmun Rev (2009) 1.01
Neurotrophins in skin biology and pathology. J Invest Dermatol (2006) 0.97
Role of NGF and neurogenic inflammation in the pathogenesis of psoriasis. Prog Brain Res (2004) 0.95
Functional role of IL-22 in psoriatic arthritis. Arthritis Res Ther (2012) 0.89
Lesional T cells and dermal dendrocytes in psoriasis plaque express increased levels of granulysin. J Am Acad Dermatol (2004) 0.88
Comparative efficacy and tolerability of 5-Loxin and AflapinAgainst osteoarthritis of the knee: a double blind, randomized, placebo controlled clinical study. Int J Med Sci (2010) 0.86
Interleukin-17-induced proliferation of fibroblast-like synovial cells is mTOR dependent. Arthritis Rheum (2011) 0.84
Clinical course of psoriasis during pregnancy. Int J Dermatol (2003) 0.80
Functional significance of nerve growth factor and its receptor (TrkA) in inflammatory arthritis. Arthritis Res Ther (2010) 0.76